AVZO-021 for advanced breast and ovarian cancers
Treatments studied
Part of Cancer, Hormones & metabolism, Skin, Women’s health & pregnancy clinical trials.
This early-stage study tests AVZO-021, a new anti-cancer medicine, in people with advanced solid tumors like specific types of breast and ovarian (or related) cancers. It’s meant to find the safest dose and look for signs the medicine can shrink tumors, especially in cancers with certain gene changes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be 18 or older and able to be up and about (ECOG 0–1).
- Have an eligible advanced cancer type (for example HR+/HER2- breast cancer or CCNE1-amplified ovarian/related cancers) and no other treatable gene driver changes.
- Have measurable tumor on scans (measurable disease by RECIST 1.1).
- Have had the right prior treatments for your cohort (for example, CDK4/6 inhibitor and hormone therapy for some groups; up to 1 prior CDK4/6 for some combination groups).
- Have enough blood counts and organ function, and be able to swallow pills/capsules.
- Not have had certain recent cancer treatments or new study drugs within the required washout window, and you must not have prior therapy with CDK2, PKMYT1, or WEE1 inhibitors (and no topoisomerase inhibitors for cohort B5).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug, AVZO-023, alone or with other treatments, for people with advanced solid tumors that have not responded to standard therapy. The goal is to see if it can shrink tumors or slow their growth.
This Phase 1 trial studies how well and how safely azenosertib (ZN-c3) works in people with advanced ovarian, fallopian tube, or peritoneal cancer. It may help by offering a new treatment option for cancers that don’t respond well to platinum chemotherapy (platinum-resistant).
This Phase 1/2 study tests a new AstraZeneca cancer drug (AZD5335) to see how safely it can be given and how well it works in people with advanced solid tumors. You may get it alone or with another treatment, and you’ll need to provide tumor information (sometimes including a biopsy) for study planning.
This Phase 1 trial tests CX-5461, a new cancer medicine, in people with certain solid tumors that have BRCA1/2 or related “HRD” gene mutations. The goal is to find out how the drug works, what dose is tolerable, and whether it can help shrink tumors.
This Phase 1/2 study tests how well a new treatment combination (VS-6766, abemaciclib, and fulvestrant) works for metastatic or hard-to-remove breast cancer that is hormone-driven (ER/PR positive) and HER2 negative. It is mainly designed to find the safest dose and then see whether it can control the cancer after it has progressed on certain prior medicines.
This trial tests a new drug called AVZO-1418, either alone or with other treatments, for people with advanced solid tumors that have spread or cannot be removed. The goal is to see if the drug is safe and effective against certain types of cancer.
Hear when a new Advanced Solid Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.